FDA reauthorization bill passes Senate committee

Share this article:
 
A funding reauthorization bill that regulates the Food and Drug Administration cleared a hurdle Wednesday when a Senate committee approved it.
 
The legislation, approved by the Health, Education, Labor and Pensions Committee, reauthorizes user fees that drug and medical device industries pay to the FDA. It also adds a new fee for companies that make generic medications, specifically allowing the government to collect $299 million each year in fees from the generic drug industry for four years.
 
If the bill passes, it also would allow FDA reviewers to speed up the clearance of products for rare disease. The language also calls for developing incentives for "development of new qualified infectious disease products (QIDPs) by providing an additional five years of market exclusivity." That could be good news for nursing homes, where infectious diseases can be deadly to vulnerable seniors.
 
Congress has to send the bill to the president by Oct. 1. To read the HELP committee's bill, click here.
Share this article:

More in News

A small team of workers responds best in emergencies, expert says

A small team of workers responds best in ...

Long-term care providers should consider a "flat" crisis management approach that relies on a core group of staff members, experts advised Wednesday at the LeadingAge annual conference.

Nursing homes have better pain and catheter management if leaders have more ...

Nursing homes led by administrators and directors of nursing with higher levels of education and certification have better outcomes on some key quality measures, according to recently published findings.

Court green-lights charges that a healthcare network underused observation stays

A whistleblower can continue to pursue charges that a Nevada healthcare network routinely admitted people as hospital inpatients when they should have been placed in observation status, a federal appeals court recently ruled.